Section Arrow
MTVA.NASDAQ
- MetaVia Inc
(Financial Status)
Quotes are at least 15-min delayed:2025/09/06 07:08 EDT
Regular Hours
Last
 0.6899
+0.003 (+0.44%)
Day High 
0.7 
Prev. Close
0.6869 
1-M High
0.6992 
Volume 
29.01K 
Bid
0.6899
Ask
0.71
Day Low
0.68 
Open
0.699 
1-M Low
0.5751 
Market Cap 
16.62M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.65 
20-SMA 0.64 
50-SMA 0.65 
52-W High 4.32 
52-W Low 0.5555 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.97/-0.95
Enterprise Value
16.68M
Balance Sheet
Book Value Per Share
0.40
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
GNPXGenprex0.2295+0.0738+47.40%0.18PE
ADAPAdaptimmune Therapeutics plc0.041-0.01-19.61%-- 
NUVBNuvation Bio3.9+0.48+14.04%-- 
KLTOKlotho Neurosciences Inc0.4851-0.0099-2.00%-- 
IOVAIovance Biotherapeutics2.49+0.29+13.18%-- 
Quotes are at least 15-min delayed:2025/09/06 07:08 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM)analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.